The following sessions will be presented at this event:
Session 1 - 3D Culture Enabling Technologies
This session centers on innovations in 3D culture enabling technologies. New functional and biology-inspired interfaces and polymer networks and their impact on 3D culture are presented. Recent developments in synthetic and natural hydrogels for embedding 3D cultures are discussed. Progress in bioreactor-type 3D cultures is discussed and automated image-guided cell injection technology for 3D matrix-embedded spheroid generation is presented. Lastly, state-of-the-art organ-on-chip platforms are presented and their application perspective relative to 3D culture systems is discussed.
Session 2 - HCS
This session will focus on applications of high throughput microscopy and multiparametric analysis (otherwise known as High Content Screening, HCS) in both basic and applied research. The development of platforms for creating 3D cellular systems will be presented. Automated imaging of 3D cellular systems is challenging as the objects are rare and the volume of data acquired is large. Advances for imaging these challenging objects will be presented. In summary, the session on HCS will present the cutting edge of screening with difficult, but physiologically highly relevant cellular systems.
Session 3 - Advances in Imaging and Analysis
The possibilities for imaging biological samples are constantly evolving as novel imaging modalities are developed and applied to ever wider areas of research. With every hardware advancement, researchers are obliged to develop methods to extract, analyse and interpret data from these images as well as re-evaluate the data that can be extracted from existing imaging modalities. This session will highlight just some of the many current and near-future techniques in both arms of this on-going evolution.
Session 4 - Stem Cells and Organoids
Stem cells offer enormous potential for the in vitro culture of human tissues, with applications in regenerative medicine and drug discovery. As the culture of functional human tissues becomes more standardised and miniaturised, they become increasingly applicable for screening purposes. This presents opportunities to screen for factors that promote survival, growth and functional differentiation of normal tissues and to screen for compounds that are active in disease models. The application of high content methods allows the full potential of these cultured tissues to be realised. As well as enabling screening in more physiologically relevant (non-immortalised) cell types, biobanks of patient derived stem cells and organoids present the opportunity to screen in tissue panels that capture patient heterogeneity, essentially representing in vitro clinical trials. This session explores these opportunities, drawing on the latest research into stem cell derived cardiac, neuronal, kidney, intestinal and various cancer organoid cultures.